Novartis agreed to acquire Synnovation’s Pikavation unit, paying $2 billion up front for a next‑generation, mutation‑selective PI3Kα inhibitor meant to defend and extend its HR+/HER2‑ breast cancer portfolio. The asset, SNV‑4818, is engineered to preferentially inhibit mutant PI3Kα and aims to reduce on‑target toxicities that have limited first‑generation PI3Kα drugs. Synnovation and its Pikavation subsidiary will transfer clinical programs and data to Novartis, which plans further trials including combination and earlier‑line studies. The deal includes up to $1 billion in development, regulatory and commercial milestones, reflecting an industry pattern of big pharma buying targeted next‑gen oncology entrants to shore up established franchises. Analysts see the purchase as a defensive move ahead of intensified competition in the PI3Kα class.